Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 284
  • Home
  • Print this page
  • Email this page

 Table of Contents  
Year : 2020  |  Volume : 15  |  Issue : 4  |  Page : 340-349

Synthesis and antileishmanial effect of a few cyclic and non-cyclic n-aryl enamino amide derivatives

1 Department of Microbiology and Parasitology, School of Medicine; Research Center for Zoonoses, Parasitic and Microbial Diseases, Ardabil University of Medical Sciences, Ardabil, I.R. Iran
2 Department of Medicinal Chemistry; Students Research Committee, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, I.R. Iran
3 Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, I.R. Iran

Date of Submission10-Feb-2020
Date of Decision27-Apr-2020
Date of Acceptance13-Aug-2020
Date of Web Publication28-Aug-2020

Correspondence Address:
Nima Razzaghi-Asl
Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil
I.R. Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1735-5362.293512

Rights and Permissions

Background and purpose: The prevalence of leishmaniasis is reported in more than 98 countries and Iran is one of the endemic areas. There is no vaccine for this disease and few effective drugs are available to treat it. Moreover, drug resistance to the disease is increasing. During the past decade, several in vitro and in vivo studies have been performed on dihydropyrimidine derivatives as antileishmanial agents.
Experimental approach: In the present project, a few 6-methyl-4-aryl-N-aryl dihydropyrimidinone/thiones (A7-A11) and N-heteroaryl-3-(para-methoxy benzyl) amino but-enamides (A1-A6) were synthesized, structurally characterized, and finally subjected to in vitro anti-leishmanial effect against Leishmania major promastigotes.
Findings / Results: Results of the study showed that compound A10, 4-(3-chlorophenyl)-6-methyl-N-phenyl- 2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, exhibited superior anti-leishmanial effect with IC50 value of 52.67 μg/mL (more active than standard drug Glucantim® with IC50 71000 ± 390 μg/mL).
Conclusion and implications: It was demonstrated that some dihydropyrimidine thiones were able to inhibit Leishmania major promastigotes. Structure-activity relationship evaluations indicated that more electron-poor rings such as isoxazole afforded higher activity within A1-A6 series and in these derivatives, N-benzothiazole rings reinforced anti-leishmanial activity concerning thiazole. It was also observed that higher anti-parasite activities of A10 and A11 concerning A7-A9 might be related to the incorporation of the sulfur atom into C2 position, replacement of N-thiazole carboxamide by N-phenyl carboxamide on C5 position of dihydropyrimidine ring, and also replacement of para with meta-substituted phenyls within C4 of dihydropyrimidine ring. The results may help unveil new 4-aryl-5-carboxamide dihydropyrimidines as potential anti-leishmanial agents and their further structural modification toward more potent derivatives.

Keywords: Dihydropyrimidinone; Leishmaniasis; MTT; Synthesis enamino amide

How to cite this article:
Mohammadi-ghalehbin B, Najafi S, Razzaghi-Asl N. Synthesis and antileishmanial effect of a few cyclic and non-cyclic n-aryl enamino amide derivatives. Res Pharma Sci 2020;15:340-9

How to cite this URL:
Mohammadi-ghalehbin B, Najafi S, Razzaghi-Asl N. Synthesis and antileishmanial effect of a few cyclic and non-cyclic n-aryl enamino amide derivatives. Res Pharma Sci [serial online] 2020 [cited 2020 Sep 28];15:340-9. Available from: http://www.rpsjournal.net/text.asp?2020/15/4/340/293512

  Introduction Top

Leishmaniasis is caused by protozoan parasites of the genus Leishmania and transferred into the host by the bite of infected female phlebotomine sandflies. Based on WHO reports, the pathogen is endemic over 90 countries [1] and Iran is one of the endemic areas of this pathogen [2],[3]. Leishmaniasis is estimated to involve about 2 million new cases per year [4] and despite such prevalence, leishmaniasis is categorized as a neglected tropical disease due to its strong relationship with poverty and also considering the limited resources invested in its diagnosis, treatment, and control [5]. Leishmania is characterized by diverse clinical manifestations that range from self-limiting cutaneous lesions to highly fatal visceral leishmaniasis [6].

Owing to the lack of effective antileishmanial vaccines up to now [4], existing leishmania therapy relies entirely on a limited number of chemotherapeutic agents such as sodium stibogluconate, meglumine antimoniate, amphotericin B, pentamidine, paromomycin, and miltefosine [7],[8]. In spite of chemotherapeutic advantages, current drugs suffer from severe adverse effects and increased incidence of treatment failures [9]. Although current chemotherapy in some regions relies on liposomal amphotericin B which is effective and less toxic than non-liposomal formulation, problems such as treatment failure and post- kala-azar dermal leishmaniasis are major concerns [10].

In the light of above explanations, continued use of present antileishmanial drugs for the treatment of leishmaniasis is restricted, and potent and selective antileishmanial agents based on new molecular scaffolds are urgently required. Nitrogen-based heterocycles are privileged medicinal structures with valuable pharmacological properties. Besides previous reports on the antileishmanial activity of similar nitrogen-containing compounds such as quinazolines [11], a few dihydropyrimidinone (DHPM) derivatives were also reported to exhibit antileishmanial activities [12],[13],[14]. To our best knowledge, previous reports mostly included DHPMs with 5-carboxylate [12], 5- alkanoyl [14], or 5-hyetroatyl [15] moieties. Fewer studies were dedicated to the antileishmanial activities of 5-carboxamide substituents and within this category, some aliphatic carboxamide derivatives were demonstrated to possess antileishmanial effects [13].

Based on previous reports and also intending to achieve more diverse structural patterns within N-heteroaryl 5-carboxamide DHPM and dihydropyrimidine thiones (DHPMT)-based antileishmanials, current work was dedicated to the synthesis, structural characterization and in vitro antileishmanial assessment of a few 6-methyl-4-aryl-N-aryl DHPM/DHPMTs (A7-A11) and some acyclic analogues with N-heteroaryl-3-(para-methoxy benzyl) amino but-enamide structure (A1-A6) against Leishmania major (L. major) promastigotes.

  Materials and Methods Top


All chemical reagents were purchased from Merck (Germany) and Aldrich (India) Companies and applied without further purification. Melting points were determined on an Electrothermal type 9200 melting point apparatus (England) and uncorrected. Infrared (IR) spectra were recorded on a Perkin Elmer- 400 FT-IR spectrophotometer (England) while proton nuclear magnetic resonance (1H NMR) spectra were obtained on a Bruker DRX400 spectrometer (400 MGHz). Mass (MS) spectra were recorded on an Agilent 7890A spectrometer.

General procedure for the synthesis of N- heteroaryl-3-(para-methoxy benzyl) amino but-enamides (A1-A6)

The initial reaction of primary aromatic amines with dioxin and xylene under reflux afforded corresponding beta-keto amides (B1-B3) [16],[17]. To explain more; 1 mmol of B1-B3 and 1.5 mmol of 4-methoxy benzylamine was dissolved in an appropriate amount of isopropyl alcohol and refluxed for 10 min to 3 h. The progress of the reaction was monitored by thin-layer chromatography (TLC) and after completion of the reaction, the precipitate was washed with cold ethanol (2 × 3 mL). The precipitate was dried in a desiccator to afford the final product (A1-A6) [Table 1].
Table 1: Synthetized derivatives of N-heteroaryl-3-(para-methoxy benzyl) amino but-enamides (A1-A6).

Click here to view

General procedure for the synthesis of 6- methyl-4-aryl-N-aryl dihydropyrimidinones (A7-A9)

B1-B6 (3.9 mmol), 3 mmol 4-fluoro benzaldehyde, and 3.6 mmol urea were dissolved in an appropriate amount of ethanol. After adding 5 drops of hydrochloric acid, the whole mixture was refluxed for 24 h. The progress of the reaction was monitored by TLC and after completion of the reaction, ice and water were added to the contents of the reflux flask. After 15 min, the formed precipitate was washed with cold water and recrystallized in ethanol. Final products were achieved after drying (A7-A9) [Table 2].
Table 2: Synthetized derivatives of 6-methyl-4-aryl-N-aryl dihydropyrimidinone/thiones (A7-A11).

Click here to view

General procedure for the synthesis of 6- methyl-4-aryl-N-aryl dihydropyrimidine thiones (A10 and A11)

N-phenyl acetoacetamide (1.2 mmol), 1.3 mmol thiourea, 0.5 mmol CO(HSO4)2 in 5 mL ethanol was added to 1 mmol corresponding aldehyde and the solution was refluxed for 24 h [18],[19]. The progress of the reaction was monitored by TLC and after completion of the reaction, ice and water were added to the contents of the reflux flask. After 15 min, the formed precipitate was washed with cold water and recrystallized in ethanol and methanol mixture. Final products were achieved after drying (A10 and A11) [Table 2].

Biological assessment

Leishmania major (MRHO/IR/75/ER) promastigotes were provided for this experiment. The parasites were cultivated in RPMI1640 supported with 10% inactivated fetal bovine serum (FBS) and 1% penicillin- streptomycin. All the parasite cultivating and cytotoxicity evaluation procedures were conducted due to the previous reports [20],[21]. Briefly, 100 μL of medium containing 2.5 × 106 promastigotes of L. major was added to each well of 96 well plates. The promastigotes were treated with 10 μL of different concentrations of all derivatives at 25 °C for 48 h. To evaluate the cytotoxic effects of the dihydropyrimidinones (DHPMs) and promastigote viability, colorimetric MTT assay was used and IC50 for each derivative was calculated [18],[19]. Glucantime was used as control. All experiments were performed triplicate and repeated three times. The IC50 values for in vitro antileishmanial activity of different concentrations were calculated using sigmoid dose-response curves generated by the software SigmaPlot version 14.

Statistical analysis

All data are presented as mean ± standard deviation (SD). Statistically significant differences among groups were determined by one-way analysis of variance (ANOVA) followed by post hoc Tukey’s test. P ≤ 0.05 were considered significant.

  Results Top


Chemical structures of all synthesized derivatives were confirmed by IR, MS, and 1H NMR methods. Spectroscopic results of synthesized compounds are illustrated below.

N-3- (4-methoxybenzylamino)-N- (6-methoxy- benzothiazol-2-yl) but-2-enamide (A1)

Yield: 56.91%, Rf = 0.695 (petroleum ether (PE) / EtOAc, 1:1), Rf = 0.839/ethanol (16 drop)/chloroform (4 mL)), mp: 225 °C; 1H NMR (DMSO-d6) μ (ppm) 11.38 (1H, brs, NH- amide), 9.36 (1H, t, J = 5.6 Hz, NH-enamine), 7.50 (1H, d, J = 8.8 Hz, C4′H-benzothiazole), 7.43 (1H, s, C7′H-benzothiazole), 7.24 (2H, d, J = 8.4 Hz, CH-phenyl), 6.94 (3H, d, J = 8.8 Hz, C5′H-benzothiazole and CH-phenyl), 4.74 (1H, s, CH-alkene), 4.41 (2H, d, J = 6 Hz, CH2- benzyl), 3.77 (3H, s, 6′-OCH3-benzothiazole), 3.74 (3H, s, Ph-OCH3), 1.95 (3H, s, CH3), IR (KBr) ν (cm-): 3204.68 (N-H, amide), 3140.62 (NH, amine) 2944.91 (CH, aromatic), 2898.43 and 2842.18 (CH, aliphatic), 1638.10 (C=O, amide), 1577.05 (C=C); 833.47 (para- disubstituted benzene), 1166.39 and 1255.24 and 1270.59 (CN), MS m/z (%): 383.1 (6) [M+], 121.1 (100), 180.1 (30),206(23), 77.1 (8).

3-(4- methoxybenzylamino)- N- (6-methyl- benzo[d]thiazol-2-yl) but-2-enamide (A2)

Yield: 77.11%, Rf = 0.575 (PE / EtOAc, 1:1), Rf = 0.818 (ethanol (16 drop) / chloroform (4 mL)), mp: 223 °C; 1H NMR (DMSO-d6) δ (ppm) 11.43 (1H, brs, NH-amide), 9.38 (1H, t, J = 6 Hz, NH-enamine), 7.63 (1H, s, C7′H-benzothiazole), 7.49 (1H, d, J = 8 Hz, C4′H- benzothiazole), 7.25 (2H, d, J = 8.8 Hz, CH-phenyl), 7.16 (1H, d, J = 8 Hz, C5′H-benzothiazole), 6.94 (2H, d, J = 8.4 Hz, CH-phenyl), 4.75 (1H, s, CH-alkene), 4.41 (2H, d, J = 6 Hz, CH2-benzyl), 3.74 (3H, s, Ph-OCH3), 2.37 (3H, s, Ph-CH3, 196 (3H, s, CH3), IR (KBr) ν (cm-1): 3187.5 (NH, amide), 3118.38 (NH, amine), 3004.35 (CH, aromatic), 2951.37 and 2921.87 (CH, aliphatic), 1641.52 (C=O, amide), 1581.76 (C=C); 818.06 (para- disubstituted benzene), 1167.33, 1248.99, and 1272.28 (CN), MS m/z (%): 367.1 (15) [M+], 121.2 (100), 164.1 (44),204.1 (44), 77.1 (19).

3-(4- methoxybenzylamino)- N- (2,3-dihydro- benzo[d]thiazol-2-yl) but-2-enamide (A3)

Yield: 99.7%, Rf = 0.609 (PE / EtOAc, 1:1), Rf = 0.826 (ethanol (16 drop) / chloroform (4 mL), mp: 222-225 °C; 1H NMR (DMSO-d6) δ (ppm) 11.51 (1H, brs, NH-amide), 9.40 (1H, t, J = 5.6 Hz, NH-enamine), 7.83 (1H, d, J = 8 Hz, C4′H-benzothiazole), 7.61 (1H, d, J = 8 Hz, C7′H-benzothiazole), 7.35 (1H, t, J = 7.2 Hz, C5′H-benzothiazole), 7.25 (2H, d, J = 8.4 Hz, CH-phenyl), 7.19 (1H, t, J = 7.6 Hz, C6′H-benzothiazole), 6.94 (2H, d, J = 8.4 Hz, CH- phenyl), 4.77 (1H, s, CH-alkene), 4.42 (2H, d, J = 5.6 Hz, CH2-benzyl), 3.74 (3H, s, OCH3- phenyl), 1.96 (3H, s, CH3), IR (KBr) ν (cm-1): 3294.01 (NH, amide), 3184.62 (NH, amine), 3128.93 (CH, aromatic), 3014.74 and 2937.41 (CH, aliphatic), 1644.65 (C=O, amide), 1578.79 (C=C); 812.51(para-disubstituted benzene), 1167.08, 1249.37, and 1278.71 (C- N), MS m/z (%): 353.1 (5) [M+], 121.1 (100), 150.1 (60),176 (21), 78.1 (19).

E-3-(4-methoxybenzylamino)-N-(thiazol-2-yl) but-2-enamide (A4)

Yield: 99.31%, Rf = 0.5 (PE / EtOAc, 1:1), Rf = 0.857 (ethanol (16 drop) / chloroform (4 mL)), mp: 218 °C; 1H NMR (DMSO-d6) δ (ppm) 11.27 (1H, brs, NH-amide), 9.30 (1H, t, J = 6 Hz, NH-enamine), 7.35 (1H, d, J = 3.6 Hz, C4′H-thiazole), 7.23 (1H, d, J = 8.8 Hz, C5′H-thiazole), 7.00 (2H, d, J = 3.6 Hz, CH-phenyl), 6.92 (2H, d, J = 6.8 Hz, CH-phenyl), 4.73 (1H, s, CH- alkene), 4.38 (2H, d, J = 6 Hz, CH2- benzyl), 3.73 (3H, s, OCH3-phenyl), 1.92 (3H, s, CH3), IR (KBr) ν (cm-1): 3274.34 (NH, amide), 3196.25 (NH, amine), 3108.96 and 3006.45 (CH, aromatic), 2937.27 and 2835.12 (CH, aliphatic), 1643.22 (C=O, amide), 1536.76 (C=C); 812.51(815.99-disubstituted benzene), 1099.16, 1170.95, and 1161.90 (CN), MS m/z (%): 303.1 (34) [M+], 121.2 (100), 204.2 (84), 77.1 (18).

3-(4- methoxybenzylamino) -N- (4-methyl- benzo[d]thiazol-2-yl) but-2-enamide (A5)

Yield: 61.58%, Rf = 0.64 (PE / EtOAc, 1:1), Rf=0.878 (ethanol (16 drop) / chloroform (4 mL)), mp: 180 °C; 1H NMR (DMSO-d6) δ (ppm) 11.59 (1H, brs, NH-amide), 9.39 (1H, t, J = 6 Hz, NH-enamine), 7.64 (1H, d, J = 7.6 Hz, C7′H-benzothiazole), 7.25 (2H, d, J = 8.8 Hz, CH-phenyl), 7.17 (1H, d, J = 7.2 Hz, C5′H-benzothiazole), 7.09 (1H, t, J = 7.6 Hz, C6′H-benzothiazole), 6.94 (2H, d, J = 8.4 Hz, CH-phenyl), 4.78 (1H, s, CH-alkene), 4.42 (2H, d, J = 6 Hz, CH2-benzyl), 3.74 (3H, s, OCH3-phenyl), 2.49 (3H, s, 4′-CH3-benzothiazole), 1.95 (3H, s, CH3), IR (KBr) ν (cm-1): 3241.87 (NH, amide), 3204.85 (NH, amine), 3046.87 (CH, aromatic), 2981.25 and 2930.97 (CH, aliphatic), 1645.01 (C=O, amide), 1582.35 (C=C); 818.37(ortho-disubstituted benzene), 1299.71, 1253.54, and 1172.19 (CN), MS m/z (%): 367.1 (15) [M+], 121.1 (100), 204.1 (20), 164.1 (38), 77.1 (18).

3-(4-methoxybenzylamino)-N-(5-methyloxazol- 2-yl) but-2-enamide (A6)

Yield: 60.87%, Rf = 0.6 (PE / EtOAc, 1:1), Rf = 0.807 (ethanol (16 drop) / chloroform(4 mL)), mp: 187-192 °C; 1H NMR (DMSO-d6) δ (ppm) 10.01 (1H, brs, NH-amide), 9.37 (1H, t, J = 6 Hz, NH-enamine), 7.21 (2H, d, J = 8.8 Hz, CH-phenyl), 6.92 (2H, d, J = 8.4 Hz, CH- phenyl), 6.60 (1H, s, C4′H-isoxazole), 4.65 (1H, s, CH-alkene), 4.35 (2H, d, J = 6 Hz, CH2- benzyl), 3.73 (3H, s, OCH3-phenyl), 2.30 (3H, s, 5′-CH3-isoxazole), 1.89 (3H, s, CH3); IR (KBr) ν (cm-1): 3234.28 (NH, amide), 3179.68 (NH, amine), 3173.99 and 3097.54 (CH, aromatic), 2964.14 and 2872.22 (CH, aliphatic), 1653.11 (C=O, amide), 1587.72 (C=C); 810.26 (para-disubstituted benzene),1176.59, 1253.30, and 1280.67 (CN), MS m/z (%): 301.1 (6) [M+], 121.2 (100), 204.1 (14), 77.1 (14).

4-(4-fluorophenyl) N-(6-methoxybenzothiazol- 2-yl)-6-methyl -2-oxo-1, 2, 3, 4 –tetrahydro- pyrimidine-5-carboxamide (A 7)

Yield: 48.35 %, Rf = 0.78 (PE / EtOAc, 1:1), Rf = 0.75 (ethanol (16 drop) / chloroform (4 mL)), mp: 245-247 °C; 1H NMR (DMSO-d6) δ (ppm) 11.39 (1H, brs, NH-amide), 9.11 (1H, brs, N1H), 7.80 (1H, brs, N3H), 7.57 (1H, d, J = 8.8 Hz, C4′H-benzothiazole), 7.50 (1H, s, C7′H-benzothiazole), 7.32 (2H, d, J = 8.8 Hz, CH-phenyl), 7.15 (2H, d, J = 8.8 Hz, CH-phenyl), 7.00 (1H, d, J = 8.8 Hz, C5′H-benzothiazole), 5.59 (1H, brs, C4H-DHPM), 3.78 (3H, s, OCH3-benzothiazole), 2.19 (3H, s, CH3-DHPM), IR (KBr) ν (cm-1): 3399.8 (brs, NH-amide and N1H urea), 3249.10 (N3H, urea), 3099.66 and 2943.56 (CH, aromatic), 1700.82 and 1593.69 (C=O, amide and urea) 1552.08 and 1477.19 (C=C, aromatic);1262.33 (CF), MS m/z (%): 412.1 (4) [M+], 191.1 (100), 165.1 (56), 231.1(16), 69.1 (11).

4-(4- fluorophenyl)-6- methyl N-(6-methyl- benzothiazol -2-yl)-2-oxo-1, 2, 3, 4-tetrahydro- pyrimidine-5-carboxamide (A8)

Yield: 31.27%, Rf = 0.717 (PE / EtOAc 1:1), Rf = 0.767 (ethanol (16 drop) / chloroform (4 mL)), mp: 217-219 °C; 1H NMR (DMSO-d6) δ (ppm) 11.83 (1H, brs, NH-amide), 9.12 (1H, brs, N1H), 7.80 (1H, brs, N3H), 7.70 (1H, brs, C7′H-benzothiazole), 7.63 (1H, d, J = 8.4 Hz, C4′H-benzothiazole), 7.58 (1H, d, J = 8.0 Hz, C5′H-benzothiazole), 7.32 (2H, d, J = 8.4 Hz, CH-phenyl), 7.17 (2H, d, J = 8.8 Hz, CH-phenyl), 5.60 (1H, brs, C4H-DHPM), 2.38 (3H, s, CH3-benothiazole), 2.19 (3H, s, CH3- DHPM), IR (KBr) ν (cm-1): 3172.68 ( brs, NH amide and N1H urea), 3072.82 (N3H, urea), 3003.72 (CH, aromatic), 1710.68 and 1658.28 (C=O, amide and urea) 1560.25 (C=C, aromatic);1314.26 (CF), MS m/z (%): 396.1 (7) [M+], 164.1 (100), 248.1 (48), 1901.1 (19), 77.1 (9).

N-(benzothiazol-2-yl)-4- (4-fluorophenyl)-6- methyl-2-oxo-1, 2, 3, 4-tetrahydropyrimidine-5- carboxamide (A9)

Yield: 41.25%, Rf = 0.38 (PE / EtOAc, 1:1), Rf = 0.5 (ethanol (16 drop) / chloroform (4 mL)), mp: 288 °C; 1H NMR (DMSO-d6) δ (ppm) 11.91 (1H, brs, NH-amide), 9.14 (1H, brs, N1H-amide), 7.91 (1H, d, J = 7.2 Hz, C4′H-benzothiazole), 7.82 (1H, brs, N3H), 7.69 (1H, d, J = 7.2 Hz, C7′H-benzothiazole), 7.41 (1H, t, J = 7.2 Hz, C5′H-benzothiazole), 7.27 (1H, t, J = 7.6 Hz, C6′H-benzothiazole), 7.33 (2H, d, J = 8.4 Hz, CH-phenyl), 7.17 (2H, d, J = 8.8 Hz, CH-phenyl), 5.61 (1H, brs, C4H-DHPM), 2.20 (3H, s, CH3-DHPM), IR (KBr) ν (cm-1): 3436.61 (brs, NH-amide and N1H urea), 3242.36 (N3H, urea), 3072.27 (CH, aromatic), 1683.16 and 1628.95 (C=O, amide and urea) 1540.50 and 1447.46 (C=C, aromatic);1243.75 (CF), MS m/z (%): 382.1 (47) [M+], 150.1 (100), 190.1 (47), 233.1(54), 69.1 (9).

4-(3-chlorophenyl) -6-methyl-N- phenyl-2- thioxo -1, 2, 3, 4- tetrahydropyrimidine-5- carboxamide (A10)

Yield: 8.73%, Rf = 0.48 (PE / EtOAc, 1:1), Rf = 0.61 (ethanol (16 drop) / chloroform (4 mL)), mp: 170 °C; 1H NMR (DMSO-d6) δ (ppm) 10.24 (1H, brs, NH-amide), 9.90 (1H, brs, N1H), 9.63 (1H, brs, N3H), 7.66 (2H, d, J = 7.6 Hz, CH-phenyl), 7.33-7.55 (7H, m, CH- phenyl), 5.51 (1H, brs, C4H-DHPM), 2.20 (3H, s, CH3-DHPM); IR (KBr) νmax (cm-1): 3413.9 (NH, amide), 3267.4 and 3185.3 (N-H, DHPM), 3066.5 and 3015.8 (CH, aromatic), 1678.5 (C=O), 1629.6 and 1584.1 (C=C, CN); MS m/z (%): 357 (63) [M+], 281 (24), 265 (100), 246 (86), 77 (25).

4-(3- fluorophenyl)-6- methyl-N- phenyl-2- thioxo -1, 2, 3, 4- tetrahydropyrimidine-5- carboxamide (A11)

Yield: 60.78%, Rf = 0.48 (PE/EtOAc, 1:1), Rf = 0.5 (ethanol (16 drop) / chloroform (4 mL)), mp: 178 °C; 1H NMR (DMSO-d6) δ (ppm) 10.23 (1H, brs, NH-amide), 9.90 (1H, brs, N1H), 9.64 (1H, brs, N3H), 7.67 (2H, d, J = 7.6 Hz, CH-phenyl), 7.22-7.57 (7H, m, CH-phenyl), 5.53 (1H, brs, C4H-DHPM), 2.20 (3H, s, CH3-DHPM); IR (KBr) νmax (cm-1): 3406.4 (NH, amide), 3174.2 and 3108.9 (NH, DHPM), 3064.3 and 3016.9 (CH, aromatic), 1678.7 (C=O), 1629.8 and 1571.4 (C=C, CN); MS m/z (%): 341 (66) [M+], 249 (100), 190 (69), 77 (23).

in vitro antileishmanial effect

Prepared N-heteroaryl enamino amides and DHPMs/DHPMTs were assessed for their antileishmanial effect against L. major promastigotes through colorimetric MTT assay within RPMI culture medium. Results were reported in terms of IC50 values with glucantime as the reference drug [Table 3]. Biological results showed that A10 and A7 were the best (IC50 52.67 μg/mL) and the worst (IC50 36566.71 μg/mL) antileishmanial derivatives. Moreover, relatively all the compounds exhibited higher antileishmanial effect than glucantime (IC50 71000 ± 390 pg/mL). For more information, the concentration-response curve for A10 is depicted in [Figure 1]. As could be seen in [Figure 1], after an initial concentration of 6.25 pg/mL, a steep decreasing slope of the curve occurred in a way that in 200 μg/mL, 0.27% of the promastigote cells were viable.
Table 3: Antileishmanial activity of dihydropyrimidine derivatives against Leishmania major promastigotes. Data are presented as mean ± SD, n = 3.

Click here to view
Figure 1: Concentration-response curve for the antileishmanial effect of compound A10 against Leishmania major promastigotes. Data represented as mean ± SD, n = 3.

Click here to view

  Discussion Top

Synthetic routes to compounds A1 to A11 are depicted in [Scheme 1] and [Scheme 2]. From the mechanistic aspect of view, synthesis of cyclic derivatives is initiated by the nucleophilic attack of the nitrogen atom in thiourea or urea into aldehyde carbonyl. After tautomerism, intramolecular nucleophilic attack and water elimination generates imine intermediate. 3- oxo butanamide carbonyl captures proton to produce enol which reacts with imine intermediate to give the second intermediate. The new intermediates are converted to target compounds via cyclization and water removal.

Synthesized derivatives were evaluated for their in vitro antileishmanial activity against L. major promastigotes. Based on obtained biological data, following structure activity relationship (SAR) guidelines may be ruled out based on two main scaffolds:

(a) N-heteroaryl amino but-enamides

  1. Among structures, different IC50s of A3, A4, and A6 could be attributed to the type of ring attached to the amide nitrogen. It was concluded that isoxazole was an electron-poor ring about thiazole and proposed a possible chemical interaction with an electron-rich site in the pathogen receptor. Such results were also reported previously in a way that neolignanes possessing isoxazole and triazole rings exhibited better antileishmanial activities than furan containing derivatives and it was also revealed that isoxazole bearing compounds were better than triazole based ones [22]. Other studies could also exhibit the effect of electron- poor or rich rings on the antileishmanial activities [23].
  2. Regarding the obtained IC50 values for compounds A1-A3, and A5, N-benzothiazolyl derivatives were better antileishmanial agents than N-thiazole one (A4) suggesting a possible hydrophobic interaction via the relevant site of the pathogen receptor.
  3. Results exhibited that in addition to the heterocycle type, the location of the substituent on the benzothiazole ring had also a significant effect on biological activity since 6-methoxy group (A1) led to the 7-fold increase in activity regarding the benzothiazole without any substituent (A3).
  4. Superior effect of A1 concerning other N-benzothiazolyl based derivatives proposed a possible H-bonding as an H-bond acceptor with the site of interaction in pathogen receptor. However, this molecular site needs further attention via the incorporation of different H- bond acceptor groups. Similar results on a few 9-methyl-1-phenyl-9H-pyrido [3,4-b] indoles indicated the importance of methoxy substituents on antileishmanial effects.

(b) Dihydropyrimidinones/thiones

  1. Within cyclic derivatives, it seemed that the replacement of 2-carbonyl with 2- thiocarbonyl moiety had a significant effect on antileishmanial inhibitory activity [24].
  2. Compound A10 (IC50: 52.67 μg/mL) and A11 (IC50: 182.55 μg/mL) were only structurally different concerning their C4 position in DHPM ring. 4-(meta-chloro phenyl) substituent led to an about 3.5-folds increase in antileishmanial effect when compared to 4- (meta-fluoro phenyl) and such observation prompted us to go through different meta- substituted corresponding derivatives in our future studies.
  3. In the case of A7-A9 no considerable antileishmanial effect could be detected and in overall it could be concluded that higher antiparasitic activities of A10 and A11 relative to A7-A9 might be related to the incorporation of sulfur atom into C2 position, replacement of 5-(N-thiazole carboxamide) by 5-(N-phenyl carboxamide) on C5 position of DHPM ring, and also replacement of para with meta substituted phenyls within C4 of DHPM ring.

In light of the above explanations, schematic SARs might be plausible for further molecular modifications into more potent antileishmanial agents [Figure 2] and [Figure 3].
Figure 2: Proposed structure-activity relationship for assessed N-heteroaryl-3-(para-methoxy benzyl) amino but-enamides (A1-A6) antileishmanial agents against Leishmania major.

Click here to view
Figure 3: Proposed structure-activity relationship for assessed 6-methyl-4-aryl-N-aryl dihydropyrimidinones/thiones (A7-A11) antileishmanial agents against Leishmania major.

Click here to view

  Conclusion Top

SAR evaluations indicated that DHPMTs with halogen on meta position of 4-phenyl ring had superior antileishmanial effect than DHPMs bearing halogen on para position of 4-phenyl ring. Moreover; the replacement of 5-(N-thiazole carboxamide) by 5-(N-phenyl carboxamide) reinforced the activity. Based on obtained results, future efforts might be directed toward synthesis and antileishmanial assessment of diverse 5-(N-phenyl carboxamide)-4-(meta-substituted phenyl)- 2-thiocarbonyl DHPMs with possible hydrophobic substituents on the N-phenyl moiety to span more extended chemical space to find potent antileishmanial small molecules.

  Acknowledgments Top

This work was financially supported by Ardabil University of Medical Sciences under Grant No. IR.ARUMS.REC.1398.110.

  Conflict of Interest Statement Top

The authors declare that they have no conflict of interest in this study.

  Authors’ Contribution Top

All authors contributed equally to this work.

  References Top

World Health Organization, WHO report on global surveillance of epidemic-prone infectious diseases- leishmaniasis. https://www.who.int/csr/resources/publications/CSR_ISR_2000_1leish/en/, visited 20 December 2019.  Back to cited text no. 1
Shirzadi MR, Esfahania SB, Mohebalia M, Ershadia MR, Gharachorlo F, Razavia MR, et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. East Mediterr Health J. 2015;21(10):736-742. DOI: 10.26719/2015.21.10.736.  Back to cited text no. 2
Sajjadi SE, Eskandarian AA, Shokoohinia Y, Yousefi HA, Mansourian M, Asgarian-Nasab H, et al. Antileishmanial activity of prenylated coumarins isolated from Ferulago angulata and Prangos asperula. Res Pharm Sci. 2016;11(4):324-331. DOI: 10.4103/1735-5362.189314.  Back to cited text no. 3
Savoia D. Recent updates and perspectives on leishmaniasis. J Infect Dev Ctries. 2015;9(6):588- 596. DOI: 10.3855/jidc.6833.  Back to cited text no. 4
Ortalli M, Ilari A, Colotti G, De Ionna I, Battista T, Bisi A, et al. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase. Eur J Med Chem. 2018;152:527-541. DOI: 1 0 .1016/j.ejmech.2018.04.057.  Back to cited text no. 5
Mendoza-Martínez C, Correa-Basurto J, Nieto-Meneses R, Marquez-Navarro A, Aguilar-Suarez R, Montero-Cortes MD, et al. Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents. Eur J Med Chem. 2015;96:296-307. DOI: 10.1016/j.ejmech.2015.04.028.  Back to cited text no. 6
Vijayakumar S, Das P. Recent progress in drug targets and inhibitors towards combating leishmaniasis. Acta Trop. 2018;181:95-104. DOI: 10.1016/j.actatropica.2018.02.010.  Back to cited text no. 7
Sheikhmoradi V, Saberi S, Saghaei L, Pestehchian N, Fassihi A. Synthesis and antileishmanial activity of antimony (V) complexes of hydroxypyranone and hydroxypyridinone ligands. Res Pharm Sci. 2018;13(2):111-120. DOI: 10.4103/1735-5362.223793.  Back to cited text no. 8
Ponte-Sucre A, Gamarro F, Dujardin J, Barret MP, Lopez-Velez R, García-Hernandez R, et al. Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052,1-24. DOI: 10.1371/journal.pntd.0006052.  Back to cited text no. 9
Bhattacharya SK, Dash AP. Elimination of Kala-Azar from the southeast Asia region. Am J Trop Med Hyg. 2017;96(4):802-804. DOI: 10.4269/ajtmh. 16-0279.  Back to cited text no. 10
Rezaee Nasab R, Hassanzadeh F, Mansourian M. Synthesis, antimicrobial evaluation and docking studies of some novel quinazolinone Schiff base derivatives. Res Pharm Sci. 2018;13(3):213-221. DOI: 10.4103/1735-5362.228942.  Back to cited text no. 11
Singh N, Kaur J, Kumar P, Gupta S, Singh N, Ghosal A, et al. An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res. 2009;105(5):1317-1325. DOI: 10.1007/s00436-009-1557-z.  Back to cited text no. 12
Saudi MNS, El-Semary MMA, Elbayaa RY, Jaeda MI, Eissa MM, Amer EI, et al. Synthesis and biological evaluation of a novel class as antileishmanial agent. Med Chem Res. 2012;21:257- 267. DOI: 10.1007/s00044-010-9532-x.  Back to cited text no. 13
Rashid U, Sultana R, Shaheen N, Hassan SF, Yaqoob F, Ahmad MJ, et al. Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents. Eur J Med Chem. 2016;115:230-244. DOI: 10.1016/j.ejmech.2016.03.022.  Back to cited text no. 14
Mishra R, Mishra B, Hari Narayana Moorthy NS. Synthesis and anti-microbial evaluation of some 3,4-dihydro pyrimidine-2-one derivatives. Trends Appl Sci Res. 2008;3(20):203-208. DOI: 10.3923/tasr.2008.203.208.  Back to cited text no. 15
Razzaghi-Asl N,Omidreza F, Hemmateenejad B, Javidnia K, Edraki N, Miri R. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4- aryl-1,4-dihydropyridines as small molecule BACE- 1 inhibitors. Bioorg Med Chem. 2013;21(22): 6893-6909. DOI: 10.1016/j.bmc.2013.09.033.  Back to cited text no. 16
Tavangar S, Bohlooli S, Razzaghi-Asl N. Synthesis and cytotoxic effect of a few N-heteroaryl enamino amides and dihydropyrimidinethiones on AGS & MCF-7 human cancer cell lines. Res Pharm Sci. 2020;15(2):154-163. DOI: 10.4103/1735-5362.283815.  Back to cited text no. 17
Memarian HR, Ranjbar M. Synthesis of Biginelli compounds using Cobalt Hydrogen sulfate. J Chin Chem Soc. 2011;58(4):522-527. DOI: 10.1002/jccs.201190016.  Back to cited text no. 18
Jalali M, Mahdavi M, Memarian HR, Ranjbar M, Soleymani M, Fassihi A, et al. Antimicrobial evaluation of some novel derivatives of 3,4-dihydropyrimidine-2(1H)-one. Res Pharm Sci. 2012;7(4):243-247.  Back to cited text no. 19
Niapour A, Bohlooli S, Sharifi Pasandi M, Mohammadi-ghalehbin B. In vitro anti leishmanial effect of Agrostemma githago extract on Leishmania major promastigotes by cell count and MTT assay. J Mazandaran Univ Med Sci. 2018;28(165):13-23.  Back to cited text no. 20
Heidari-Kharaji M, Fallah-Omrani V, Badirzadeh A, Mohammadi-Ghalehbin B, Nilforoushzadeh MA, Masoori L, et al. Sambucus ebulus extract stimulates cellular responses in cutaneous leishmaniasis. Parasite Immunol. 2019;41(1) :e12605,1-37. DOI: 10.1111/pim.12605.  Back to cited text no. 21
das Neves AR, Trefzger OS, Barbosa NV, Honorato AM, Carvalho DB, Moslaves IS, et al. Effect of isoxazole derivatives of tetrahydrofuran neolignans on intracellular amastigotes of Leishmania (Leishmania) amazonensis: a structure-activity relationship comparative study with triazole-neolignan-based compounds. Chem Biol Drug Des. 2019;94(6):2004-2012. DOI: 10.1111/cbdd.13609.  Back to cited text no. 22
Liu M, Wilairat P, Croft SL, Tan AL, Go ML. Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg Med Chem. 2003;11(13):2729-2738. DOI: 10.1016/s0968-0896(03)00233-5.  Back to cited text no. 23
Ashok P, Chander S, Smith TK, Prakash Singh R, Jha PN, Sankaranarayanan M. Biological evaluation and structure activity relationship of 9-methyl-1- phenyl-9H-pyrido [3, 4-b] indole derivatives as anti-leishmanial agents. Bioorg Chem. 2019;84: 98-105. DOI: 10.1016/j.bioorg.2018.11.037.  Back to cited text no. 24


  [Figure 1], [Figure 2], [Figure 3]

  [Table 1], [Table 2], [Table 3]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Materials and Me...
Conflict of Inte...
Authors’ C...
   Article Figures
   Article Tables

 Article Access Statistics
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal